Amandeep Godara, MBBS

home / authors / amandeep-godara-mbbs

Articles

Amandeep Godara, MBBS

Dr Godara on the Selection of CAR T-Cell Therapies vs Bispecific Antibodies in R/R Multiple Myeloma

Amandeep Godara, MBBS
April 13th 2023

Amandeep Godara, MBBS, discusses important patient factors to consider when deciding between a CAR T-cell therapy vs bispecific antibody in relapsed/refractory multiple myeloma, and the importance of mitigating treatment-related toxicities associated with the administration of bispecific antibodies in this disease setting.

Read More

Amandeep Godara, MBBS

Dr. Godara on Approved CAR T-cell Therapies in Multiple Myeloma

Amandeep Godara, MBBS
March 21st 2023

Amandeep Godara, MBBS, discusses CAR T-cell therapies currently available for patients with multiple myeloma.

Read More

Amandeep Godara, MBBS

Dr. Godara on Treatment Strategies Following First Relapse in Multiple Myeloma

Amandeep Godara, MBBS
March 8th 2023

Amandeep Godara, MBBS, discusses the current treatment strategies following first relapse for patients with multiple myeloma.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data